Is It Time to Rethink the Age-Old Practice of Permissive Hyperkalemia in Renin-Angiotensin-Aldosterone Inhibition?
- PMID: 34015068
- PMCID: PMC8116968
- DOI: 10.1016/j.ekir.2021.03.895
Is It Time to Rethink the Age-Old Practice of Permissive Hyperkalemia in Renin-Angiotensin-Aldosterone Inhibition?
Comment on
-
Hyperkalemia and its Association With Mortality, Cardiovascular Events, Hospitalizations, and Intensive Care Unit Admissions in a Population-Based Retrospective Cohort.Kidney Int Rep. 2021 Mar 17;6(5):1309-1316. doi: 10.1016/j.ekir.2021.02.038. eCollection 2021 May. Kidney Int Rep. 2021. PMID: 34013109 Free PMC article.
References
-
- Kosiborod M., Rasmussen H., Lavin P. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE Randomized Clinical Trial. JAMA. 2014;312:2223–2233. - PubMed
-
- Bakris G., Pitt B., Weir M. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314:151–161. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources